A Multicenter Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial to Determine the Antiviral Activity, Pharmacokinetics, Tolerability and Safety of RDEA806 in HIV-1 Positive, Antiretroviral naive Subjects.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs RDEA 806 (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Ardea Biosciences
- 24 May 2010 Results have been published in Antimicrobial Agents and Chemotherapy.
- 25 Oct 2008 Results were presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America - A Joint Meeting.
- 03 Aug 2008 Results presented at the XVII International AIDS Conference 2008.